Lundbeck targets fast-growing migraine market with Vyepti filing

Danish CNS company Lundbeck (CPH: LUND) has had its new drug application for Vyepti (eptinezumab) accepted by Japan’s health ministry, marking a major step toward expanding its presence in Asia. The company is pursuing approvals in China and South Korea as part of a regional push in preventive migraine treatment.

If cleared, this would be Lundbeck’s first marketing authorization in Japan and its first biologic launch in China and South Korea. Johan Luthman, executive vice president and head of research and development, said the regulatory progress represents “a critical milestone in Lundbeck’s Asian development program for eptinezumab,” adding that migraine prevention remains significantly underused across East Asia.

Lundbeck generated around $3.2 billion in revenue in 2024, with strategic brands showing strong growth. The migraine-drug market itself was valued at roughly $6.8 billion in 2024 and could nearly double by 2030. Demand in Japan is set to rise, with market forecasts pointing to more than $560 million in annual sales by 2035.